New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
08:14 EDTACURAcura Pharma downgraded to Hold from Buy at MLV & Co.
MLV & Co. Acura following the announcement that the FDA advised the company that the data from the company's intranasal abuse liability study AP-ADF-301 for the company's AVERSION hydrocodone bitartrate with acetaminophen product candidate are insufficient to support an intranasal abuse deterrence claim.
News For ACUR From The Last 14 Days
Check below for free stories on ACUR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2014
06:18 EDTACURAcura Pharma awarded NIH grant to fund drug abuse deterrent technology
Acura Pharmaceuticals has been awarded a $300K grant by the National Institute On Drug Abuse of the National Institutes of Health to fund Phase I development of Acura's new, early stage Limitx abuse deterrent technology. The Grant is based on a proposal submitted by the company to advance the development of a self-regulating hydromorphone tablet intended to deter abuse by excess oral consumption of the tablets. The company must complete Phase I development by February 28, 2015. Phase I of the project is intended to optimize the formulation in preparation for clinical testing in Phase II. NIDA funding of Phase II development, for which an application has already been submitted, will be contingent upon Phase I progress, approval of other documents and availability of funds.
August 15, 2014
06:17 EDTACURAcura announces preliminary discussions held with FDA for acetaminophen tablet
Acura Pharmaceuticals announced preliminary discussions from a meeting held with the FDA regarding the development pathway for Acura's AVERSION hydrocodone with acetaminophen tablet development candidate, which is intended to provide abuse-deterrent features to address abuse by nasal snorting and injection. In a May 2014 letter to Acura, FDA questioned the relevance of abuse of hydrocodone with acetaminophen products by nasal snorting after reviewing clinical and epidemiology data submitted by Acura. The FDA continues to question the relevance of abuse of hydrocodone with acetaminophen products by the intranasal route of administration and suggested additional information may help better inform their decision. The FDA indicated in the discussions that Acura may conduct an additional nasal abuse liability study for its AVERSION hydrocodone with acetaminophen product candidate, the outcomes of which may help inform the relevance decision as well as establish a reduction in drug liking, which was not statistically significant in an earlier Acura study. The FDA requested further time to deliberate on the issues discussed during the meeting before issuing final meeting minutes. Acura intends to review its clinical data from Study AP-ADF-301 to determine whether to proceed with an additional clinical study for its AVERSION hydrocodone with acetaminophen product candidate and to further evaluate options to address the issues of intranasal abuse and drug liking raised by the FDA.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use